Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin

Alok Kothari, Alexander Ngwube, Robert Hayashi, Lisa Murray, Jeffrey Davis, Paul Haut, Brett J. Loechelt, Shalini Shenoy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Genetically derived hematologic cytopenias are a rare heterogeneous group of disorders. Allogeneic hematopoietic cell transplantation (HCT) is curative but offset by organ toxicities from the preparative regimen, graft rejection, graft-versus-host disease (GVHD), or mortality. Because of these possibilities, consideration of HCT can be delayed, especially in the unrelated donor setting. We report a prospective multicenter trial of reduced-intensity conditioning (RIC) with alemtuzumab, fludarabine, and melphalan and HCT in 11 children with marrow failure of genetic origin (excluding Fanconi anemia) using the best available donor source (82% from unrelated donors). The median age at transplantation was 23 months (range, 2 months to 14 years). The median times to neutrophil (>500× 10<sup>6</sup>/L) and platelet (>50× 10<sup>9</sup>/L) engraftment were 13 (range, 12 to 24) and 30 (range, 7 to 55) days, respectively. The day+100 probability of grade II to IV acute GVHD and the 1-year probability of limited and extensive GVHD were 9% and 27%, respectively. The probability of 5-year overall and event-free survival was 82%; 9 patients were alive with normal blood counts at last follow-up and all were successfully off systemic immunosuppression. In patients with genetically derived severe hematologic cytopenias, allogeneic HCT with this RIC regimen was successful in achieving a cure. This experience supports consideration of HCT early in such patients even in the absence of suitable related donors.

Original languageEnglish
Pages (from-to)1321-1325
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume21
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Cell Transplantation
Graft vs Host Disease
Unrelated Donors
Tissue Donors
Fanconi Anemia
Melphalan
Graft Rejection
Immunosuppression
Multicenter Studies
Disease-Free Survival
Neutrophils
Blood Platelets
Transplantation
Bone Marrow
Mortality

Keywords

  • Congenital hematologic cytopenias
  • Hematopoietic cell transplantation
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. / Kothari, Alok; Ngwube, Alexander; Hayashi, Robert; Murray, Lisa; Davis, Jeffrey; Haut, Paul; Loechelt, Brett J.; Shenoy, Shalini.

In: Biology of Blood and Marrow Transplantation, Vol. 21, No. 7, 01.07.2015, p. 1321-1325.

Research output: Contribution to journalArticle

Kothari, Alok ; Ngwube, Alexander ; Hayashi, Robert ; Murray, Lisa ; Davis, Jeffrey ; Haut, Paul ; Loechelt, Brett J. ; Shenoy, Shalini. / Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. In: Biology of Blood and Marrow Transplantation. 2015 ; Vol. 21, No. 7. pp. 1321-1325.
@article{008a0e74c13e4c0d9c46aa4bf5f151f2,
title = "Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin",
abstract = "Genetically derived hematologic cytopenias are a rare heterogeneous group of disorders. Allogeneic hematopoietic cell transplantation (HCT) is curative but offset by organ toxicities from the preparative regimen, graft rejection, graft-versus-host disease (GVHD), or mortality. Because of these possibilities, consideration of HCT can be delayed, especially in the unrelated donor setting. We report a prospective multicenter trial of reduced-intensity conditioning (RIC) with alemtuzumab, fludarabine, and melphalan and HCT in 11 children with marrow failure of genetic origin (excluding Fanconi anemia) using the best available donor source (82{\%} from unrelated donors). The median age at transplantation was 23 months (range, 2 months to 14 years). The median times to neutrophil (>500× 106/L) and platelet (>50× 109/L) engraftment were 13 (range, 12 to 24) and 30 (range, 7 to 55) days, respectively. The day+100 probability of grade II to IV acute GVHD and the 1-year probability of limited and extensive GVHD were 9{\%} and 27{\%}, respectively. The probability of 5-year overall and event-free survival was 82{\%}; 9 patients were alive with normal blood counts at last follow-up and all were successfully off systemic immunosuppression. In patients with genetically derived severe hematologic cytopenias, allogeneic HCT with this RIC regimen was successful in achieving a cure. This experience supports consideration of HCT early in such patients even in the absence of suitable related donors.",
keywords = "Congenital hematologic cytopenias, Hematopoietic cell transplantation, Reduced-intensity conditioning",
author = "Alok Kothari and Alexander Ngwube and Robert Hayashi and Lisa Murray and Jeffrey Davis and Paul Haut and Loechelt, {Brett J.} and Shalini Shenoy",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.bbmt.2015.03.019",
language = "English",
volume = "21",
pages = "1321--1325",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin

AU - Kothari, Alok

AU - Ngwube, Alexander

AU - Hayashi, Robert

AU - Murray, Lisa

AU - Davis, Jeffrey

AU - Haut, Paul

AU - Loechelt, Brett J.

AU - Shenoy, Shalini

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Genetically derived hematologic cytopenias are a rare heterogeneous group of disorders. Allogeneic hematopoietic cell transplantation (HCT) is curative but offset by organ toxicities from the preparative regimen, graft rejection, graft-versus-host disease (GVHD), or mortality. Because of these possibilities, consideration of HCT can be delayed, especially in the unrelated donor setting. We report a prospective multicenter trial of reduced-intensity conditioning (RIC) with alemtuzumab, fludarabine, and melphalan and HCT in 11 children with marrow failure of genetic origin (excluding Fanconi anemia) using the best available donor source (82% from unrelated donors). The median age at transplantation was 23 months (range, 2 months to 14 years). The median times to neutrophil (>500× 106/L) and platelet (>50× 109/L) engraftment were 13 (range, 12 to 24) and 30 (range, 7 to 55) days, respectively. The day+100 probability of grade II to IV acute GVHD and the 1-year probability of limited and extensive GVHD were 9% and 27%, respectively. The probability of 5-year overall and event-free survival was 82%; 9 patients were alive with normal blood counts at last follow-up and all were successfully off systemic immunosuppression. In patients with genetically derived severe hematologic cytopenias, allogeneic HCT with this RIC regimen was successful in achieving a cure. This experience supports consideration of HCT early in such patients even in the absence of suitable related donors.

AB - Genetically derived hematologic cytopenias are a rare heterogeneous group of disorders. Allogeneic hematopoietic cell transplantation (HCT) is curative but offset by organ toxicities from the preparative regimen, graft rejection, graft-versus-host disease (GVHD), or mortality. Because of these possibilities, consideration of HCT can be delayed, especially in the unrelated donor setting. We report a prospective multicenter trial of reduced-intensity conditioning (RIC) with alemtuzumab, fludarabine, and melphalan and HCT in 11 children with marrow failure of genetic origin (excluding Fanconi anemia) using the best available donor source (82% from unrelated donors). The median age at transplantation was 23 months (range, 2 months to 14 years). The median times to neutrophil (>500× 106/L) and platelet (>50× 109/L) engraftment were 13 (range, 12 to 24) and 30 (range, 7 to 55) days, respectively. The day+100 probability of grade II to IV acute GVHD and the 1-year probability of limited and extensive GVHD were 9% and 27%, respectively. The probability of 5-year overall and event-free survival was 82%; 9 patients were alive with normal blood counts at last follow-up and all were successfully off systemic immunosuppression. In patients with genetically derived severe hematologic cytopenias, allogeneic HCT with this RIC regimen was successful in achieving a cure. This experience supports consideration of HCT early in such patients even in the absence of suitable related donors.

KW - Congenital hematologic cytopenias

KW - Hematopoietic cell transplantation

KW - Reduced-intensity conditioning

UR - http://www.scopus.com/inward/record.url?scp=84930573060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930573060&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2015.03.019

DO - 10.1016/j.bbmt.2015.03.019

M3 - Article

C2 - 25840334

AN - SCOPUS:84930573060

VL - 21

SP - 1321

EP - 1325

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -